Allogene Therapeutics, Inc. (ALLO) Free cash flow 2018–2025
Allogene Therapeutics, Inc. (ALLO) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$149.6MFY2025 · since FY2018: -$47.9M → -$149.6M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$149.6M | +25.6% |
| FY2024 | -$201.0M | +16.0% |
| FY2023 | -$239.2M | -6.0% |
| FY2022 | -$225.7M | -9.4% |
| FY2021 | -$206.3M | -13.9% |
| FY2020 | -$181.1M | +3.8% |
| FY2019 | -$188.1M | -292.9% |
| FY2018 | -$47.9M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice